Fresenius Kabi Launches Idacio (biosimilar- adalimumab) for Multiple Chronic Inflammatory Conditions in Canada
Shots:
- Health Canada has authorized Idacio on Oct 30- 2020- for marketing in Canada and is now available for all indications of the reference (Humira) in the field of rheumatology- gastroenterology and dermatology
- Health Canada’s approval was based on analytical- pre/ clinical data that demonstrated similar PK- efficacy- safety and immunogenicity to the Humira. Idacio is the first Fresenius Kabi’s biosimilar introduced in North America
- KAbiCare is a patient support program that provides patients with information- tools- support during the treatment and offers reimbursement navigation- financial assistance- as well as customized services to help an individual in clinic processes
Ref: Newswire Canada | Image: Fresenius Kabi
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
